Frontier Medicines Appoints Former Seagen CEO David Epstein to Board as Company Advances Covalent Precision Medicine Pipeline
Key Insights
Frontier Medicines (search) appointed David R. Epstein (search), former CEO of Seagen and Novartis Pharmaceuticals, to its board of directors to support the company's next phase of growth.
Epstein brings over 30 years of drug development experience and played a central role in developing more than 30 new molecular entities and over 100 approved indications.
The appointment comes as Frontier advances its pipeline of covalent precision medicines, including FMC-242 (search) and FMC-376, targeting previously undruggable proteins in oncology and immunology.
Frontier Medicines (search) Corporation, a clinical-stage precision medicines company, announced the appointment of David R. Epstein (search) to its board of directors. Epstein currently serves as chairman and CEO of Ottimo Pharma (search) and was most recently CEO of Seagen, where he led the company through significant growth and innovation before its acquisition by Pfizer in 2023.
Veteran Executive Brings Extensive Drug Development Experience
Epstein brings more than 30 years of global drug development and commercialization experience to support Frontier's next phase of growth as it continues to advance its pipeline of covalent precision medicines. During his career, he has played a central role in the development and commercialization of more than 30 new molecular entities and over 100 approved indications, including breakthrough medicines such as Gleevec, Tasigna, Gilenya, Afinitor, Cosentyx, Padcev and Entresto.
"David is a transformative leader with an exceptional track record of building and scaling innovative biopharmaceutical organizations," said Chris Varma, Ph.D., co-founder, chairman, and chief executive officer of Frontier Medicines (search). "His deep expertise across oncology, global drug development and commercialization will be invaluable as we advance our pipeline, continue to expand the reach of the Frontier Platform and work to develop breakthrough medicines for patients."
Leadership Track Record in Oncology
Epstein previously served as chief executive officer of Novartis Pharmaceuticals, a division of Novartis AG. Prior to this role, he started and led Novartis' Oncology and Molecular Diagnostic units, and under his leadership, the company's oncology business grew to the second largest in the world. He currently serves on the boards of several biotechnology companies, including Valo Health, Agomab and Tempus AI.
Advancing Precision Medicine Pipeline
Frontier Medicines (search) is developing small molecule oncology and immunology drugs against previously undruggable disease-causing targets. The company's pipeline includes potentially best-in-class programs such as FMC-242 (search), an allosteric breaker of the PI3Kα-RAS (search) interaction, and FMC-376, a KRAS G12C (search) ON and OFF inhibitor with promising clinical data.
"Frontier Medicines (search) is working to redefine what's possible in drug discovery with a pipeline of potentially best-in-class programs," said Epstein. "Supported by a platform that integrates covalent chemistry and AI to expand the reach of precision medicine, Frontier is well positioned to make a meaningful impact for patients. I look forward to advancing this work alongside the company's experienced leadership team."
Proprietary Platform Technology
The Frontier Platform integrates chemoproteomics, artificial intelligence, and direct-to-biology approaches to accelerate the discovery and development of precision covalent medicines. The platform maps covalent binding sites across the proteome, identifies actionable ligands, and enables rapid optimization of compounds into clinical candidates.
Years of systematic data generation have produced CoGT (the Covalent Ground Truth), which powers Frontier's CovalentAI engine. This AI component characterizes and scores binding sites for covalent drug discovery, optimizes compounds, and guides the design of Frontier's proprietary covalent fragment library. Profiling this library against the human proteome has yielded Frontier's Druggability Atlas, covering more than 90% of the human proteome.